Bofanglutide (GZR18)
GLP-1 · s.c. every 2 weeks · Gan & Lee
Summary
- Also known as
- Gan & Lee
- Mechanism
- GLP-1
- Route
- s.c. every 2 weeks
- Company
- Gan & Lee
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 GRADUAL-1 positive (48 mg every 2 weeks: −18.5 % at 52 weeks); US phase 2; once-monthly GRADUAL-3 started verify
- Next milestone
- NDA in China
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 GRADUAL-1 (52 weeks); GRADUAL-3 once-monthly maintenance after GRADUAL-1: weight +0.41 % / −0.12 % vs +8.52 % with placebo over 24 weeks (topline release, November 2026) | Gan & Lee release, 4 Nov 2026 |
| T2D | 2 phase 3 ongoing | Phase 3 ongoing | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2b CTR20231695 | 12 mg Q2W | obesity china | 30 | 52 | — | —−11.2 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| Phase 2b CTR20231695 | 18 mg Q2W | obesity china | 30 | 53 | — | —−13.2 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| Phase 2b CTR20231695 | 24 mg Q2W | obesity china | 30 | 52 | — | —−14.2 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| Phase 2b CTR20231695 | 48 mg Q2W | obesity china | 30 | 64 | — | —−17.3 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| Phase 2b CTR20231695 | 24 mg QW | obesity china | 30 | 53 | — | —−17.8 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| Phase 2b CTR20232069 (vs semaglutide) | 12 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −1.9 | — | — | — | — | — | — | press release |
| Phase 2b CTR20232069 (vs semaglutide) | 18 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −2.3 | — | — | — | — | — | — | press release |
| Phase 2b CTR20232069 (vs semaglutide) | 24 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −1.9 | — | — | — | — | — | — | press release |
| Phase 2b CTR20232069 (vs semaglutide) | 24 mg QW vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −2.3 | — | — | — | — | — | — | press release |
| US Phase 2 (NCT06737042) | 48 mg Q2W vs tirzepatide 15 mg QW (open-label active comparator): weight -16.93 % | obesity | 36 | 326 | — | —−15.2 % estimand not specified | — | — | — | — | — | — | — | press release |
| GRADUAL-1 (NCT06728124) | 24 mg Q2W | obesity china | 52 | 640 | — | —−15.1 % vs −1.1 % estimand not specified | — | — | — | — | — | — | — | press release |
| GRADUAL-1 (NCT06728124) | 48 mg Q2W | obesity china | 52 | 640 | — | —−18.5 % vs −1.1 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (17)
- 12 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 12 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 18 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 18 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 24 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 24 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 48 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 48 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 24 mg QW · weight_unsp · press release
In the QW 24 mg group, participants experienced a weight reduction of 17.78% (1.01)
- 24 mg QW · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 12 mg Q2W · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 18 mg Q2W · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 24 mg Q2W · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 24 mg QW · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 24 mg Q2W · weight_unsp · press release
achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
- 48 mg Q2W · weight_unsp · press release
achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
- 48 mg Q2W · weight_unsp · press release
the 48 mg bofanglutide injection group achieved an average weight loss of 15.18%
Registered trials (9)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| BALANCE-OBS BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity | Obesity | Phase 3 | not yet recruiting | 2026-09 → 2027-12 | 352 | not yet recruiting | NCT07622810 |
| NCT07628985 BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | T2D | Phase 3 | not yet recruiting | 2026-09 → 2027-10 | 374 | not yet recruiting | NCT07628985 |
| NCT07493057 Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | Sleep apnoea | Phase 3 | recruiting | 2026-04 → 2027-11 | 140 | recruiting | NCT07493057 |
| NCT07501832 Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy | Sleep apnoea | Phase 3 | recruiting | 2026-04 → 2028-09 | 140 | recruiting | NCT07501832 |
| GZR18-BWM-303 Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Obesity | Phase 3 | completed | 2026-01 → 2026-09 | 224 | Completed; results not in the atlas yet | NCT07292441 |
| NCT07150975 Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | Obesity | Phase 3 | recruiting | 2025-09 → 2027-06 | 420 | recruiting | NCT07150975 |
| Optimum 1 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise | T2D | Phase 3 | completed | 2025-02 → 2026-07 | 274 | Completed; results not in the atlas yet | NCT06777238 |
| Optimum 2 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2025-02 → 2026-09 | 1133 | Completed; results not in the atlas yet | NCT06778967 |
| NCT06728124 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects | Obesity | Phase 3 | completed | 2024-12 → 2026-03 | 640 | Completed; results not in the atlas yet | NCT06728124 |
Primary sources
- Gan & Lee. ObesityWeek 2024: Gan & Lee orally presents Phase 2b clinical data for GZR18 injection in Chinese overweight and obese adults (BioSpace mirror of PR Newswire) [press release]. 2024-11-11. Available from: https://www.biospace.com/press-releases/obesityweek-2024-gan-lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults
- Gan & Lee. Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18, GZR4 and GZR101 Achieve Primary Endpoints in Phase 2 Clinical Studies (BioSpace mirror of PR Newswire/CNW) [press release]. 2024-10-15. Available from: https://www.biospace.com/press-releases/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and-gzr101-injection-achieve-primary-endpoints-in-phase-2-clinical-studies
- Gan & Lee. Gan & Lee: Insulin Ludefen meets Phase III endpoint; Bofanglutide meets primary endpoints in Phase III weight-loss study in China (GRADUAL-1) and Phase II in the U.S. (Macau Business mirror of PR Newswire) [press release]. 2026-06-12. Available from: https://macaubusiness.com/gan-lee-pharmaceuticals-achieves-significant-progress-in-its-dual-pipeline-for-metabolic-diseases-weekly-insulin-ludefen-gzr4-meets-primary-endpoint-in-phase-iii-clinical-trial-in-china-bo/
How to cite this page
Cite the primary publication for any single result; every value above links to it.